Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5486737 | 1.00 | ADRA2A (0.41) | ADRA2AADRA2BADRA2CADRB1ADRB3 | |
| SCHEMBL22051464 | 0.79 | CES2 (0.35) | ADRA2AADRA2BADRA2CADRB1ADRB3 | |
| SCHEMBL31376555 | 0.79 | SLC18A3 (0.43) | SLC18A3SIGMAR1 | |
| SCHEMBL29811265 | 0.79 | SLC18A3 (0.43) | SLC18A3SIGMAR1 | |
| SCHEMBL4975851 | 0.79 | SLC18A3 (0.43) | SLC18A3SIGMAR1 | |
| SCHEMBL16959073 | 0.79 | GABRA1 (0.31) | ADRA2AADRA2BADRA2CADRB1ADRB3 | |
| SCHEMBL611730 | 0.79 | ADRA2A (0.37) | ADRA2AADRA2BADRA2CADRB1ADRB3 | |
| SCHEMBL14837162 | 0.79 | ADRA2A (0.37) | ADRA2AADRA2BADRA2CADRB1ADRB3 | |
| SCHEMBL30910218 | 0.76 | CES2 (0.33) | ADRA2AADRA2BADRA2CADRB1ADRB3 | |
| SCHEMBL30967943 | 0.76 | HTR2C (0.37) | ADRA2AADRA2BADRA2CADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076367-B2 | Benzimidazolylidene propane-1,3-dione derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20100173946-A1 | BENZIMIDAZOLYLIDENE PROPANE-1,3-DIONE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2010-07-08 | — | — | US | disclosed |
| US-7709519-B2 | Benzimidazolylidene propane-1,3 dione derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2010-05-04 | — | — | US | disclosed |
| US-20090018177-A1 | Propane-1,3-Dione Derivative or Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018177-A1 | Propane-1,3-Dione Derivative or Salt Thereof | GPER1, GNRHR, AR | ADRA2A 327/4885ADRA2B 363/4885ADRA2C 489/4885 |
| US-20100173946-A1 | BENZIMIDAZOLYLIDENE PROPANE-1,3-DIONE DERIVATIVE OR SALT THEREOF | GPER1, GNRHR, AR | ADRA2A 526/4885ADRA2B 510/4885ADRA2C 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.